A Duke University professor has been appointed chief medical officer at Alcon, the company announced.
Terry Kim
Dr. Terry Kim, chief of the Duke Eye Center’s Cornea and External Disease Division and Director of Refractive Surgery Service, will join the company this month.
As CMO, Kim will continue to integrate scientific and clinical priorities across Alcon’s Surgical and Vision Care franchises, according to a press release. Kim will also support the development of surgical and vision care research, and represent Alcon to academic, scientific and industry communities, as well as government agencies.
Kim will succeed Dr. Stephen S. Lane, who is retiring after seven years at Alcon and 39 years in ophthalmology.
“Dr. Kim is an exceptional addition to our team, and we look forward to leveraging his world-class cataract-refractive experience to build upon the efforts spearheaded by Dr. Lane,” said Franck Leveiller, Alcon chief scientific officer and Global Head R&D, in a statement. “Bringing Dr. Kim to Alcon is a testament to our ongoing commitment in leveraging experts to inform our innovations aimed at meeting the evolving needs of Eye Care Professionals and their patients. Dr. Kim’s expertise — in partnership with leading industry professionals — will help us continue to advance our mission to deliver bold innovations.”
Kim received his medical degree from Duke University School of Medicine and completed his ophthalmic training at Emory Eye Center and Wills Eye Hospital in Philadelphia.
He has served as past president of the American Society of Cataract and Refractive Surgery and has received multiple awards throughout his career, including the Achievement Award and the Senior Achievement Award from the American Academy of Ophthalmology.
Kim serves on multiple boards, sits on the editorial board for several peer-reviewed journals and trade publications, and consults for the Food and Drug Administration’s Ophthalmic Devices Panel.
Lane “played a critical role” in advancing Alcon innovations, while supporting cornerstone initiatives, including the development of Clareon®, Vivity®, and next-generation instrumentation, as well as the acquisition of ophthalmic pharmaceuticals.